136 related articles for article (PubMed ID: 16895480)
1. Tripeptidyl-peptidase I in health and disease.
Golabek AA; Kida E
Biol Chem; 2006 Aug; 387(8):1091-9. PubMed ID: 16895480
[TBL] [Abstract][Full Text] [Related]
2. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
Bernardini F; Warburton MJ
Biochem J; 2002 Sep; 366(Pt 2):521-9. PubMed ID: 12038963
[TBL] [Abstract][Full Text] [Related]
3. [Tripeptidyl-peptidase I--distribution, biogenesis, and mechanisms of activation].
Gołabek AA
Postepy Biochem; 2006; 52(1):16-23. PubMed ID: 16869297
[TBL] [Abstract][Full Text] [Related]
4. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis.
Kopan S; Sivasubramaniam U; Warburton MJ
Biochem Biophys Res Commun; 2004 Jun; 319(1):58-65. PubMed ID: 15158442
[TBL] [Abstract][Full Text] [Related]
5. Ser475, Glu272, Asp276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I.
Walus M; Kida E; Wisniewski KE; Golabek AA
FEBS Lett; 2005 Feb; 579(6):1383-8. PubMed ID: 15733845
[TBL] [Abstract][Full Text] [Related]
6. Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.
Steinfeld R; Steinke HB; Isbrandt D; Kohlschütter A; Gärtner J
Hum Mol Genet; 2004 Oct; 13(20):2483-91. PubMed ID: 15317752
[TBL] [Abstract][Full Text] [Related]
7. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.
Sondhi D; Peterson DA; Giannaris EL; Sanders CT; Mendez BS; De B; Rostkowski AB; Blanchard B; Bjugstad K; Sladek JR; Redmond DE; Leopold PL; Kaminsky SM; Hackett NR; Crystal RG
Gene Ther; 2005 Nov; 12(22):1618-32. PubMed ID: 16052206
[TBL] [Abstract][Full Text] [Related]
8. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis.
Ezaki J; Takeda-Ezaki M; Oda K; Kominami E
Biochem Biophys Res Commun; 2000 Feb; 268(3):904-8. PubMed ID: 10679303
[TBL] [Abstract][Full Text] [Related]
9. Expression and analysis of CLN2 variants in CHO cells: Q100R represents a polymorphism, and G389E and R447H represent loss-of-function mutations.
Lin L; Lobel P
Hum Mutat; 2001 Aug; 18(2):165. PubMed ID: 11462245
[TBL] [Abstract][Full Text] [Related]
10. Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I.
Golabek AA; Kida E; Walus M; Wujek P; Mehta P; Wisniewski KE
J Biol Chem; 2003 Feb; 278(9):7135-45. PubMed ID: 12488460
[TBL] [Abstract][Full Text] [Related]
11. Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders.
Wisniewski KE; Kida E; Walus M; Wujek P; Kaczmarski W; Golabek AA
Eur J Paediatr Neurol; 2001; 5 Suppl A():73-9. PubMed ID: 11589013
[TBL] [Abstract][Full Text] [Related]
12. Detection of tripeptidyl peptidase I activity in living cells by fluorogenic substrates.
Steinfeld R; Fuhrmann JC; Gärtner J
J Histochem Cytochem; 2006 Sep; 54(9):991-6. PubMed ID: 16782851
[TBL] [Abstract][Full Text] [Related]
13. Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I.
Walus M; Kida E; Golabek AA
Hum Mutat; 2010 Jun; 31(6):710-21. PubMed ID: 20340139
[TBL] [Abstract][Full Text] [Related]
14. [Tripeptidyl peptidase 1 deficiency in neuronal ceroid lipofuscinosis. A novel mutation].
Bukina AM; Tsvetkova IV; Semiachkina AN; Il'ina ES
Vopr Med Khim; 2002; 48(6):594-8. PubMed ID: 12698559
[TBL] [Abstract][Full Text] [Related]
15. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.
Sleat DE; Wiseman JA; El-Banna M; Kim KH; Mao Q; Price S; Macauley SL; Sidman RL; Shen MM; Zhao Q; Passini MA; Davidson BL; Stewart GR; Lobel P
J Neurosci; 2004 Oct; 24(41):9117-26. PubMed ID: 15483130
[TBL] [Abstract][Full Text] [Related]
16. Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity.
Tsiakas K; Steinfeld R; Storch S; Ezaki J; Lukacs Z; Kominami E; Kohlschütter A; Ullrich K; Braulke T
Glycobiology; 2004 Apr; 14(4):1C-5C. PubMed ID: 14736728
[TBL] [Abstract][Full Text] [Related]
17. Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2).
Oyama H; Fujisawa T; Suzuki T; Dunn BM; Wlodawer A; Oda K
J Biochem; 2005 Aug; 138(2):127-34. PubMed ID: 16091586
[TBL] [Abstract][Full Text] [Related]
18. Prenatal testing for late infantile neuronal ceroid lipofuscinosis.
Berry-Kravis E; Sleat DE; Sohar I; Meyer P; Donnelly R; Lobel P
Ann Neurol; 2000 Feb; 47(2):254-7. PubMed ID: 10665500
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of late-infantile neuronal ceroid lipofuscinosis: a new sensitive method to assay lysosomal pepstatin-insensitive proteinase activity in human and animal specimens by capillary electrophoresis.
Viglio S; Marchi E; Wisniewski K; Casado B; Cetta G; Iadarola P
Electrophoresis; 2001 Jul; 22(11):2343-50. PubMed ID: 11504071
[TBL] [Abstract][Full Text] [Related]
20. Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase.
Ezaki J; Takeda-Ezaki M; Kominami E
J Biochem; 2000 Sep; 128(3):509-16. PubMed ID: 10965052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
